
1. proc natl acad sci u a. 2018 dec 4;115(49):12513-12518. doi:
10.1073/pnas.1813386115. epub 2018 nov 19.

artemisinin resistance phenotypes k13 inheritance plasmodium falciparum 
cross aotus model.

sá jm(1), kaslow sr(1), krause ma(1), melendez-muniz va(1), salzman re(1), kite
wa(1), zhang m(2), moraes barros rr(1), mu j(1), han pk(1), mershon jp(1), figan 
ce(1), caleon rl(1), rahman rs(1), gibson tj(1), amaratunga c(1), nishiguchi
ep(1), breglio kf(1), engels tm(3), velmurugan s(4), ricklefs s(5), straimer
j(6), gnädig nf(6), deng b(1), liu a(1), diouf a(1), miura k(1), tullo gs(1),
eastman rt(1), chakravarty s(4), james er(4), udenze k(2), li s(2), sturdevant
de(5), gwadz rw(1), porcella sf(5), long ca(1), fidock da(6)(7), thomas ml(3),
fay mp(8), sim bkl(4), hoffman sl(4), adams jh(2), fairhurst rm(1), su xz(1),
wellems te(9).

author information: 
(1)laboratory malaria vector research, national institute allergy and
infectious diseases, national institutes health, bethesda, md 20892.
(2)center global health infectious diseases research, college public
health, university south florida, tampa, fl 33612.
(3)division veterinary research, office research services, national
institutes health, bethesda, md 20892.
(4)sanaria, rockville, md 20850.
(5)research technology branch, national institute allergy infectious
diseases, national institutes health, hamilton, mt 59840.
(6)department microbiology immunology, columbia university college of
physicians surgeons, new york, ny 10032.
(7)division infectious diseases, department medicine, columbia university
college physicians surgeons, new york, ny 10032.
(8)biostatistics research branch, national institute allergy infectious
diseases, national institutes health, rockville, md 20852.
(9)laboratory malaria vector research, national institute allergy and
infectious diseases, national institutes health, bethesda, md 20892;
twellems@niaid.nih.gov.

concerns malaria parasite resistance treatment artemisinin drugs
(arts) grown findings prolonged parasite clearance 1/2s (>5 h) and
their association mutations plasmodium falciparum kelch-propeller protein
k13. here, describe p. falciparum laboratory cross k13 c580y mutant 
c580 wild-type parasites investigate art response phenotypes vitro in
vivo. genotyping >400 isolated progeny, evaluated 20 recombinants in
vitro: ic50 measurements dihydroartemisinin similar low nanomolar
levels c580y- c580-type progeny (mean ratio, 1.00; 95% ci, 0.62-1.61),
whereas, ring-stage survival assay, c580y-type progeny 19.6-fold
(95% ci, 9.76-39.2) higher average counts. splenectomized aotus monkeys
treated three daily doses i.v. artesunate, 1/2 calculations three
different methods yielded mean differences 0.01 h (95% ci, -3.66 3.67),
0.80 h (95% ci, -0.92 2.53), 2.07 h (95% ci, 0.77-3.36) c580y 
c580 infections. incidences recrudescence 57% c580y (4 7) versus
70% c580 (7 10) infections (-13% difference; 95% ci, -58% 35%). allelic 
substitution c580 c580y-containing progeny clone (76h10) yielded a
transformant (76h10c580rev) that, infected monkey, recrudesced regularly 13
times 500 d. frequent recrudescences art-treated p. falciparum infections
occur without k13 mutations emphasize need improved partner
drugs effectively eliminate parasites persist art
component combination therapy.

doi: 10.1073/pnas.1813386115 
pmcid: pmc6298093
pmid: 30455312  [indexed medline]

conflict interest statement: conflict interest statement: r.m.f. d.e.g.
are coauthors paper published 2017. n.f.g., d.a.f., d.e.g. are
coauthors papers published 2016 2018. k.m., c.a.l., d.e.g. are
coauthors paper published 2014. r.s.r. s.r.m. coauthors papers
published 2015 2017.

